Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.

“Our presence at the 2023 AAN Annual Meeting further reflects Jazz’s scientific leadership in developing therapies for debilitating sleep disorders and rare epilepsy syndromes that advance treatment for people living with these conditions,” said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. “Jazz has long been at the forefront of providing novel therapies and support for patients living with serious neurologic conditions. We look forward to presenting these findings, as they provide another opportunity to highlight the impact of our medicines and educate about the unmet needs our pipeline is dedicated to addressing.”

Highlights at the 2023 AAN Annual Meeting include:

• Three posters demonstrating the impact of Xywav^® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, on narcolepsy patients. Presentations include interim results from the SEGUE study of adults with narcolepsy transitioning from Xyrem^®, a high-sodium oxybate, to Xywav, a study that explored the increased incidents and risk of hypertension onset among patients with narcolepsy newly treated with Xyrem, and long-term safety results from a clinical trial of Xywav in patients with narcolepsy type 1.
• An oral presentation of a post hoc analysis evaluating treatment response to Xywav on Epworth Sleepiness Scale (ESS) and Idiopathic Hypersomnia Severity Scale (IHSS) scores within a Phase 3 clinical trial. Results demonstrate that the strong majority (80%) of participants achieved a clinically meaningful response on the ESS and IHSS, with response rates increasing over the course of the study. The safety profile of Xywav was consistent with that observed in narcolepsy.
• Subgroup analyses of the BECOME survey of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex^® (cannabidiol) oral solution, which reported on patients’ seizure- and non-seizure related outcomes, including seizure frequency, seizure-free days, alertness, cognition and executive function, and emotional and social function.
• Two oral presentations of retrospective analyses of U.S. healthcare claims that estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in adult and pediatric patients. These analyses found ET affects over 525,000 adults and that most of these patients (over 70%) received regimens not indicated as first-line for ET, suggesting the need for novel therapies for this disorder.